EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth.
Investigation of the mechanisms responsible for aggressive neuroblastoma and its poor prognosis is critical to identify novel therapeutic targets and improve survival. Enhancer of Zeste Homolog 2 (EZH2) is known to play a key role in supporting the malignant phenotype in several cancer types and kno...
Main Authors: | Laura V Bownes, Adele P Williams, Raoud Marayati, Laura L Stafman, Hooper Markert, Colin H Quinn, Nikita Wadhwani, Jamie M Aye, Jerry E Stewart, Karina J Yoon, Elizabeth Mroczek-Musulman, Elizabeth A Beierle |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0246244 |
Similar Items
-
Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma
by: Laura V. Bownes, et al.
Published: (2022-04-01) -
Targeting High-Risk Neuroblastoma Patient-Derived Xenografts with Oncolytic Virotherapy
by: Colin H. Quinn, et al.
Published: (2022-02-01) -
Serine-Threonine Kinase Receptor-Associated Protein (STRAP) Knockout Decreases the Malignant Phenotype in Neuroblastoma Cell Lines
by: Laura V Bownes, et al.
Published: (2021-06-01) -
PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma
by: Raoud Marayati, et al.
Published: (2021-03-01) -
UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line Xenografts
by: Adele P. Williams, et al.
Published: (2019-10-01)